m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00325)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
MET
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
Cell Line | LX2 cell line | Homo sapiens |
Treatment: shMETTL3 LX2 cells
Control: shLuc LX2 cells
|
GSE207909 | |
Regulation |
|
logFC: 6.42E-01 p-value: 3.45E-17 |
More Results | Click to View More RNA-seq Results |
In total 3 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | Chidamide could decrease Hepatocyte growth factor receptor (c-Met/MET) expression by inhibiting mRNA N6-methyladenosine (m6A) modification through the downregulation of METTL3 and WTAP expression, subsequently increasing the crizotinib sensitivity of NSCLC cells in a c-MET-/HGF-dependent manner. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
Responsed Drug | Crizotinib | Approved | ||
Pathway Response | EGFR tyrosine kinase inhibitor resistance | hsa01521 | ||
In-vitro Model | HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 |
NCI-H661 | Lung large cell carcinoma | Homo sapiens | CVCL_1577 | |
NCI-H596 | Lung adenosquamous carcinoma | Homo sapiens | CVCL_1571 | |
NCI-H460 | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | |
NCI-H358 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1559 | |
NCI-H292 | Lung mucoepidermoid carcinoma | Homo sapiens | CVCL_0455 | |
NCI-H1975 | Lung adenocarcinoma | Homo sapiens | CVCL_1511 | |
NCI-H1650 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1483 | |
NCI-H1395 | Lung adenocarcinoma | Homo sapiens | CVCL_1467 | |
EBC-1 | Lung squamous cell carcinoma | Homo sapiens | CVCL_2891 | |
Calu-3 | Lung adenocarcinoma | Homo sapiens | CVCL_0609 | |
A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
In-vivo Model | HCC827 (3×106) cells suspended in 100 uL of PBS were injected into the left inguen of female Balb/c nude mice (body weight 18-20 g; age 6 weeks; Beijing Huafukang Bioscience Co., Inc.). When the tumor volumes reached 50-100 mm3 on the 10th posttransplantation day, the mice were randomized into four groups (10 mice per group) and were intragastrically administered vehicle (normal saline), crizotinib (25 mg/kg body weight), chidamide (5 mg/kg), or the combination of the two drugs daily for 21 days. The tumor volumes and body weights of the mice were measured every 3 days. | |||
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | METTL3 combines with Hepatocyte growth factor receptor (c-Met/MET) and causes the PI3K/AKT signalling pathway to be manipulated, which affects the sensitivity of lung cancer cells to gefitinib. METTL3 knockdown promotes apoptosis and inhibits proliferation of lung cancer cells. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Lung cancer | ICD-11: 2C25 | ||
Responsed Drug | Gefitinib | Approved | ||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
In-vitro Model | PC-9 | Lung adenocarcinoma | Homo sapiens | CVCL_B260 |
NCI-H3255 | Lung adenocarcinoma | Homo sapiens | CVCL_6831 | |
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene | [3] | |||
Response Summary | METTL3-mediated m6A RNA methylation modulates uveal melanoma cell proliferation, migration, and invasion by targeting Hepatocyte growth factor receptor (c-Met/MET). Cycloleucine (Cyc) was used to block m6 A methylation in UM cells. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Melanoma of uvea | ICD-11: 2D0Y | ||
Pathway Response | Cell cycle | hsa04110 | ||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
Arrest cell cycle at G1 phase | ||||
In-vitro Model | M17 (Neuroblastoma cells) | |||
M21 | Melanoma | Homo sapiens | CVCL_D031 | |
M23 | Cutaneous melanoma | Homo sapiens | CVCL_RT32 | |
SP-6.5 | Uveal melanoma | Homo sapiens | CVCL_7997 | |
Wilms tumor 1-associating protein (WTAP) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by WTAP | ||
Cell Line | mouse embryonic stem cells | Mus musculus |
Treatment: WTAP-/- ESCs
Control: Wild type ESCs
|
GSE145309 | |
Regulation |
|
logFC: -2.39E+00 p-value: 1.81E-38 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | Chidamide could decrease Hepatocyte growth factor receptor (c-Met/MET) expression by inhibiting mRNA N6-methyladenosine (m6A) modification through the downregulation of METTL3 and WTAP expression, subsequently increasing the crizotinib sensitivity of NSCLC cells in a c-MET-/HGF-dependent manner. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
Responsed Drug | Crizotinib | Approved | ||
Pathway Response | EGFR tyrosine kinase inhibitor resistance | hsa01521 | ||
In-vitro Model | HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 |
NCI-H661 | Lung large cell carcinoma | Homo sapiens | CVCL_1577 | |
NCI-H596 | Lung adenosquamous carcinoma | Homo sapiens | CVCL_1571 | |
NCI-H460 | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | |
NCI-H358 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1559 | |
NCI-H292 | Lung mucoepidermoid carcinoma | Homo sapiens | CVCL_0455 | |
NCI-H1975 | Lung adenocarcinoma | Homo sapiens | CVCL_1511 | |
NCI-H1650 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1483 | |
NCI-H1395 | Lung adenocarcinoma | Homo sapiens | CVCL_1467 | |
EBC-1 | Lung squamous cell carcinoma | Homo sapiens | CVCL_2891 | |
Calu-3 | Lung adenocarcinoma | Homo sapiens | CVCL_0609 | |
A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
In-vivo Model | HCC827 (3×106) cells suspended in 100 uL of PBS were injected into the left inguen of female Balb/c nude mice (body weight 18-20 g; age 6 weeks; Beijing Huafukang Bioscience Co., Inc.). When the tumor volumes reached 50-100 mm3 on the 10th posttransplantation day, the mice were randomized into four groups (10 mice per group) and were intragastrically administered vehicle (normal saline), crizotinib (25 mg/kg body weight), chidamide (5 mg/kg), or the combination of the two drugs daily for 21 days. The tumor volumes and body weights of the mice were measured every 3 days. | |||
Lung cancer [ICD-11: 2C25]
In total 3 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | Chidamide could decrease Hepatocyte growth factor receptor (c-Met/MET) expression by inhibiting mRNA N6-methyladenosine (m6A) modification through the downregulation of METTL3 and WTAP expression, subsequently increasing the crizotinib sensitivity of NSCLC cells in a c-MET-/HGF-dependent manner. | |||
Responsed Disease | Non-small-cell lung carcinoma [ICD-11: 2C25.Y] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Drug | Crizotinib | Approved | ||
Pathway Response | EGFR tyrosine kinase inhibitor resistance | hsa01521 | ||
In-vitro Model | HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 |
NCI-H661 | Lung large cell carcinoma | Homo sapiens | CVCL_1577 | |
NCI-H596 | Lung adenosquamous carcinoma | Homo sapiens | CVCL_1571 | |
NCI-H460 | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | |
NCI-H358 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1559 | |
NCI-H292 | Lung mucoepidermoid carcinoma | Homo sapiens | CVCL_0455 | |
NCI-H1975 | Lung adenocarcinoma | Homo sapiens | CVCL_1511 | |
NCI-H1650 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1483 | |
NCI-H1395 | Lung adenocarcinoma | Homo sapiens | CVCL_1467 | |
EBC-1 | Lung squamous cell carcinoma | Homo sapiens | CVCL_2891 | |
Calu-3 | Lung adenocarcinoma | Homo sapiens | CVCL_0609 | |
A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
In-vivo Model | HCC827 (3×106) cells suspended in 100 uL of PBS were injected into the left inguen of female Balb/c nude mice (body weight 18-20 g; age 6 weeks; Beijing Huafukang Bioscience Co., Inc.). When the tumor volumes reached 50-100 mm3 on the 10th posttransplantation day, the mice were randomized into four groups (10 mice per group) and were intragastrically administered vehicle (normal saline), crizotinib (25 mg/kg body weight), chidamide (5 mg/kg), or the combination of the two drugs daily for 21 days. The tumor volumes and body weights of the mice were measured every 3 days. | |||
Experiment 2 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | METTL3 combines with Hepatocyte growth factor receptor (c-Met/MET) and causes the PI3K/AKT signalling pathway to be manipulated, which affects the sensitivity of lung cancer cells to gefitinib. METTL3 knockdown promotes apoptosis and inhibits proliferation of lung cancer cells. | |||
Responsed Disease | Lung cancer [ICD-11: 2C25] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Drug | Gefitinib | Approved | ||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
In-vitro Model | PC-9 | Lung adenocarcinoma | Homo sapiens | CVCL_B260 |
NCI-H3255 | Lung adenocarcinoma | Homo sapiens | CVCL_6831 | |
Experiment 3 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | Chidamide could decrease Hepatocyte growth factor receptor (c-Met/MET) expression by inhibiting mRNA N6-methyladenosine (m6A) modification through the downregulation of METTL3 and WTAP expression, subsequently increasing the crizotinib sensitivity of NSCLC cells in a c-MET-/HGF-dependent manner. | |||
Responsed Disease | Non-small-cell lung carcinoma [ICD-11: 2C25.Y] | |||
Target Regulator | Wilms tumor 1-associating protein (WTAP) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Drug | Crizotinib | Approved | ||
Pathway Response | EGFR tyrosine kinase inhibitor resistance | hsa01521 | ||
In-vitro Model | HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 |
NCI-H661 | Lung large cell carcinoma | Homo sapiens | CVCL_1577 | |
NCI-H596 | Lung adenosquamous carcinoma | Homo sapiens | CVCL_1571 | |
NCI-H460 | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | |
NCI-H358 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1559 | |
NCI-H292 | Lung mucoepidermoid carcinoma | Homo sapiens | CVCL_0455 | |
NCI-H1975 | Lung adenocarcinoma | Homo sapiens | CVCL_1511 | |
NCI-H1650 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1483 | |
NCI-H1395 | Lung adenocarcinoma | Homo sapiens | CVCL_1467 | |
EBC-1 | Lung squamous cell carcinoma | Homo sapiens | CVCL_2891 | |
Calu-3 | Lung adenocarcinoma | Homo sapiens | CVCL_0609 | |
A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
In-vivo Model | HCC827 (3×106) cells suspended in 100 uL of PBS were injected into the left inguen of female Balb/c nude mice (body weight 18-20 g; age 6 weeks; Beijing Huafukang Bioscience Co., Inc.). When the tumor volumes reached 50-100 mm3 on the 10th posttransplantation day, the mice were randomized into four groups (10 mice per group) and were intragastrically administered vehicle (normal saline), crizotinib (25 mg/kg body weight), chidamide (5 mg/kg), or the combination of the two drugs daily for 21 days. The tumor volumes and body weights of the mice were measured every 3 days. | |||
Melanoma of uvea [ICD-11: 2D0Y]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [3] | |||
Response Summary | METTL3-mediated m6A RNA methylation modulates uveal melanoma cell proliferation, migration, and invasion by targeting Hepatocyte growth factor receptor (c-Met/MET). Cycloleucine (Cyc) was used to block m6 A methylation in UM cells. | |||
Responsed Disease | Melanoma of uvea [ICD-11: 2D0Y] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Cell cycle | hsa04110 | ||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
Arrest cell cycle at G1 phase | ||||
In-vitro Model | M17 (Neuroblastoma cells) | |||
M21 | Melanoma | Homo sapiens | CVCL_D031 | |
M23 | Cutaneous melanoma | Homo sapiens | CVCL_RT32 | |
SP-6.5 | Uveal melanoma | Homo sapiens | CVCL_7997 | |
Crizotinib
[Approved]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | Chidamide could decrease Hepatocyte growth factor receptor (c-Met/MET) expression by inhibiting mRNA N6-methyladenosine (m6A) modification through the downregulation of METTL3 and WTAP expression, subsequently increasing the crizotinib sensitivity of NSCLC cells in a c-MET-/HGF-dependent manner. | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
Pathway Response | EGFR tyrosine kinase inhibitor resistance | hsa01521 | ||
In-vitro Model | HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 |
NCI-H661 | Lung large cell carcinoma | Homo sapiens | CVCL_1577 | |
NCI-H596 | Lung adenosquamous carcinoma | Homo sapiens | CVCL_1571 | |
NCI-H460 | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | |
NCI-H358 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1559 | |
NCI-H292 | Lung mucoepidermoid carcinoma | Homo sapiens | CVCL_0455 | |
NCI-H1975 | Lung adenocarcinoma | Homo sapiens | CVCL_1511 | |
NCI-H1650 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1483 | |
NCI-H1395 | Lung adenocarcinoma | Homo sapiens | CVCL_1467 | |
EBC-1 | Lung squamous cell carcinoma | Homo sapiens | CVCL_2891 | |
Calu-3 | Lung adenocarcinoma | Homo sapiens | CVCL_0609 | |
A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
In-vivo Model | HCC827 (3×106) cells suspended in 100 uL of PBS were injected into the left inguen of female Balb/c nude mice (body weight 18-20 g; age 6 weeks; Beijing Huafukang Bioscience Co., Inc.). When the tumor volumes reached 50-100 mm3 on the 10th posttransplantation day, the mice were randomized into four groups (10 mice per group) and were intragastrically administered vehicle (normal saline), crizotinib (25 mg/kg body weight), chidamide (5 mg/kg), or the combination of the two drugs daily for 21 days. The tumor volumes and body weights of the mice were measured every 3 days. | |||
Experiment 2 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | Chidamide could decrease Hepatocyte growth factor receptor (c-Met/MET) expression by inhibiting mRNA N6-methyladenosine (m6A) modification through the downregulation of METTL3 and WTAP expression, subsequently increasing the crizotinib sensitivity of NSCLC cells in a c-MET-/HGF-dependent manner. | |||
Target Regulator | Wilms tumor 1-associating protein (WTAP) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
Pathway Response | EGFR tyrosine kinase inhibitor resistance | hsa01521 | ||
In-vitro Model | HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 |
NCI-H661 | Lung large cell carcinoma | Homo sapiens | CVCL_1577 | |
NCI-H596 | Lung adenosquamous carcinoma | Homo sapiens | CVCL_1571 | |
NCI-H460 | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | |
NCI-H358 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1559 | |
NCI-H292 | Lung mucoepidermoid carcinoma | Homo sapiens | CVCL_0455 | |
NCI-H1975 | Lung adenocarcinoma | Homo sapiens | CVCL_1511 | |
NCI-H1650 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1483 | |
NCI-H1395 | Lung adenocarcinoma | Homo sapiens | CVCL_1467 | |
EBC-1 | Lung squamous cell carcinoma | Homo sapiens | CVCL_2891 | |
Calu-3 | Lung adenocarcinoma | Homo sapiens | CVCL_0609 | |
A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
In-vivo Model | HCC827 (3×106) cells suspended in 100 uL of PBS were injected into the left inguen of female Balb/c nude mice (body weight 18-20 g; age 6 weeks; Beijing Huafukang Bioscience Co., Inc.). When the tumor volumes reached 50-100 mm3 on the 10th posttransplantation day, the mice were randomized into four groups (10 mice per group) and were intragastrically administered vehicle (normal saline), crizotinib (25 mg/kg body weight), chidamide (5 mg/kg), or the combination of the two drugs daily for 21 days. The tumor volumes and body weights of the mice were measured every 3 days. | |||
Gefitinib
[Approved]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [2] | |||
Response Summary | METTL3 combines with Hepatocyte growth factor receptor (c-Met/MET) and causes the PI3K/AKT signalling pathway to be manipulated, which affects the sensitivity of lung cancer cells to gefitinib. METTL3 knockdown promotes apoptosis and inhibits proliferation of lung cancer cells. | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Lung cancer | ICD-11: 2C25 | ||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
In-vitro Model | PC-9 | Lung adenocarcinoma | Homo sapiens | CVCL_B260 |
NCI-H3255 | Lung adenocarcinoma | Homo sapiens | CVCL_6831 | |
References